Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Thousands tracked in psoriasis drug safety registry

NCT ID NCT02786186

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed over 2,300 adults with moderate to severe plaque psoriasis to see how safe and effective secukinumab is in everyday medical practice. Researchers recorded side effects and how well the drug cleared skin symptoms. The goal was to gather real-world evidence, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,376 people

The number who actually took part.

Started

Dec 2015

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with moderate to severe plaque psoriasis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \- Patients able to give written informed consent 2. \- Patients at least 18 years of age at time of informed consent signature 3. \- Confirmed diagnosis of chronic moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment. 4. \- Patients initiating a treatment for psoriasis as per regional policy. This will include secukinumab, other biologics, systemic treatments, and phototherapy. Decision to treat with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study. 5. \- Treatments prescribed in accordance to the product monograph and regional regulatory and reimbursement policies 6. \- Patients able to understand and communicate with the investigator and comply with the requirements of the study. Exclusion Criteria: 1. \- Unwillingness or inability to comply with the study requirements 2. \- Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Novartis Investigative Site

    Edmonton, Alberta, T6G 1C3, Canada

  • Novartis Investigative Site

    Nanaimo, British Columbia, V9T 1W1, Canada

  • Novartis Investigative Site

    Surrey, British Columbia, V3R 6A7, Canada

  • Novartis Investigative Site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Novartis Investigative Site

    Brandon, Manitoba, R7A 0L5, Canada

  • Novartis Investigative Site

    Winnepeg, Manitoba, R3M1Z9, Canada

  • Novartis Investigative Site

    Winnipeg, Manitoba, R3C 0N2, Canada

  • Novartis Investigative Site

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Novartis Investigative Site

    St. John's, Newfoundland and Labrador, A1A 4Y3, Canada

  • Novartis Investigative Site

    St. John's, Newfoundland and Labrador, A1C 2H5, Canada

  • Novartis Investigative Site

    Hamilton, Ontario, L8N 3Z5, Canada

  • Novartis Investigative Site

    London, Ontario, N6A 3H7, Canada

  • Novartis Investigative Site

    Nepean, Ontario, K2G 6E2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.